Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Sopherion gets US FDA fast track status for Myocet in metastatic breast cancer
Sopherion gets US FDA fast track status for Myocet in metastatic breast cancer
Sopherion gets US FDA fast track status for Myocet in metastatic breast cancer
Submitted by
admin
on January 9, 2010 - 12:51pm
Source:
Pharmabiz
News Tags:
Sopherion
Myocet
breast cancer
Headline:
Sopherion gets US FDA fast track status for Myocet in metastatic breast cancer
Do Not Allow Advertisers to Use My Personal information
